Surgical Treatment of Malignant Melanoma. Practical Guidelines

Dermatologic Clinics

Volumn 30, Issue 3, 2012, Pages 487-501

  Levine, Steven M ^a   Shapiro, Richard L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cutaneous malignany; Malignant melanoma; Skin cancer; Surgical treatment

Indexed keywords

IMATINIB; LACTATE DEHYDROGENASE;

CANCER MORTALITY; CANCER RISK; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CUTANEOUS MELANOMA; DISTANT METASTASIS; FACE TUMOR; FULL THICKNESS SKIN GRAFT; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MELANOMA; ONCOLOGICAL PARAMETERS; PLANTAR MELANOMA; PRACTICE GUIDELINE; PREGNANCY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SATELLITE METASTASIS; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN METASTASIS; SPLIT THICKNESS SKIN GRAFT; SUBUNGUAL MELANOMA; SURGICAL APPROACH; SURVIVAL RATE; TUMOR RECURRENCE; TUMOR THICKNESS; WOUND CLOSURE;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84863876687     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.04.009     Document Type: Review

References (122)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8-31. 31.
2. Forty-five years of cancer incidence in Connecticut: 1935-79. Natl Cancer Inst Monogr 1986, 70:1-706.
3. Glass A.G., Hoover R.N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989, 262:2097-2100.
4. Rigel D.S. Trends in dermatology: melanoma incidence. Arch Dermatol 2010, 146:318.
5. Rigel D.S. Epidemiology of melanoma. Semin Cutan Med Surg 2010, 29:204-209.
6. Cummins D.L., Cummins J.M., Pantle H., et al. Cutaneous malignant melanoma. Mayo Clin Proc 2006, 81:500-507.
7. American Academy of Dermatology Melanoma fact sheet 2010, American Academy of Dermatology, Schaumburg (IL).
8. Friedman R.J., Rigel D.S., Kopf A.W. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985, 35:130-151.
9. Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987, 258:3146-3154.
10. Weir H.K., Thun M.J., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95:1276-1299.
11. Balch C.M., Soong S.J., Shaw H., et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. Cutaneous melanoma 1992, 165-187. JB Lippincott, Philadelphia. 2nd edition. C.M. Balch, A. Houghton, G. Milton (Eds.).
12. Ross M.I., Stern S.J., Wanebo H.J. Mucosal melanomas. Cutaneous melanoma 1992, 325-335. JB Lippincott, Philadelphia. 2nd edition. C.M. Balch, A. Houghton, G. Milton (Eds.).
13. Reintgen D.S., McCarty K.S., Woodard B., et al. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet 1983, 156:335-340.
14. Giuliano A.E., Moseley H.S., Morton D.L. Clinical aspects of unknown primary melanoma. Ann Surg 1980, 191:98-104.
15. Balch C.M., Soong S.J., Murad T.M., et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981, 193:377-388.
16. Milton G.W., Shaw H.M., McCarthy W.H. Occult primary malignant melanoma: factors influencing survival. Br J Surg 1977, 64:805-808.
17. Gilchrest B.A., Eller M.S., Geller A.C., et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340:1341-1348.
18. Mogensen M., Jemec G.B. The potential carcinogenic risk of tanning beds: clinical guidelines and patient safety advice. Cancer Manag Res 2010, 2:277-282.
19. Rigel D.S., Rivers J.K., Kopf A.W., et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989, 63:386-389.
20. MacKie R.M., Freudenberger T., Aitchison T.C. Personal risk-factor chart for cutaneous melanoma. Lancet 1989, 2:487-490.
21. Ackerman A.B. What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 1988, 13:241-256.
22. Rigel D.S., Friedman R.J., Kopf A.W., et al. Precursors of malignant melanoma. Problems in computing the risk of malignant melanoma arising in dysplastic and congenital nevocytic nevi. Dermatol Clin 1985, 3:361-365.
23. Gruber S.B., Barnhill R.L., Stenn K.S., et al. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989, 21:773-780.
24. Hendrickson M.R., Ross J.C. Neoplasms arising in congenital giant nevi: morphologic study of seven cases and a review of the literature. Am J Surg Pathol 1981, 5:109-135.
25. Illig L., Weidner F., Hundeiker M., et al. Congenital nevi less than or equal to 10 cm as precursors to melanoma: 52 cases, a review, and a new conception. Arch Dermatol 1985, 121:1274-1281.
26. Rhodes A.R., Melski J.W. Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982, 100:219-224.
27. Koh H.K. Cutaneous melanoma. N Engl J Med 1991, 325:171-182.
28. Mihm M.C., Fitzpatrick T.B., Brown M.M., et al. Early detection of primary cutaneous malignant melanoma. A color atlas. N Engl J Med 1973, 289:989-996.
29. Wick M.M., Sober A.J., Fitzpatrick T.B., et al. Clinical characteristics of early cutaneous melanoma. Cancer 1980, 45:2684-2686.
30. Rigel D.S., Russak J., Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010, 60:301-316.
31. Oh T.S., Bae E.J., Ro K.W., et al. Acral lentiginous melanoma developing during long-standing atypical melanosis: usefulness of dermoscopy for detection of early acral melanoma. Ann Dermatol 2011, 23:400-404.
32. Monheit G., Cognetta A.B., Ferris L., et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol 2011, 147:188-194.
33. Scheibner A., Milton G.W., McCarthy W.H., et al. Multiple primary melanoma-a review of 90 cases. Australas J Dermatol 1982, 23:1-8.
34. Veronesi U., Cascinelli N., Bufalino R. Evaluation of the risk of multiple primaries in malignant cutaneous melanoma. Tumori 1976, 62:127-130.
35. Reimer R.R., Clark W.H., Greene M.H., et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978, 239:744-746.
36. Mai P.L., Chatterjee N., Hartge P., et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS One 2009, 4:e4812.
37. Warycha M.A., Zakrzewski J., Ni Q., et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (
38. Porter G.A., Ross M.I., Berman R.S., et al. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. Surgery 2000, 128:306-311.
39. Harris M.N., Gumport S.L. Biopsy technique for malignant melanoma. J Dermatol Surg 1975, 1:24-27.
40. Zager J.S., Hochwald S.N., Marzban S.S., et al. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011, 212:454-460. [discussion: 460-2].
41. Gown A.M., Vogel A.M., Hoak D., et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986, 123:195-203.
42. Wick M.R., Swanson P.E., Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 1988, 15:201-207.
43. Cochran A.J., Wen D.R. S-100 protein as a marker for melanocytic and other tumours. Pathology 1985, 17:340-345.
44. Nakajima T., Watanabe S., Sato Y., et al. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982, 50:912-918.
45. Thompson J.F., Soong S.J., Balch C.M., et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011, 29:2199-2205.
46. Callender G.G., McMasters K.M. What does ulceration of a melanoma mean for prognosis?. Adv Surg 2011, 45:225-236.
47. Maurichi A., Miceli R., Camerini T., et al. Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior. Ann Surg 2010, 252:1052-1057.
48. Carvajal R.D., Antonescu C.R., Wolchok J.D., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305:2327-2334.
49. Scheier B., Amaria R., Lewis K., et al. Novel therapies in melanoma. Immunotherapy 2011, 3:1461-1469.
50. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908.
51. Clark W.H., From L., Bernardino E.A., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-727.
52. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th edition. New York, London: Springer. p. xiv, 648.
53. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
54. Gershenwald J.E., Soong S.J., Balch C.M. 2010 TNM staging system for cutaneous melanoma and beyond. Ann Surg Oncol 2010, 17:1475-1477.
55. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
56. Buzaid A.C., Colome M., Bedikian A., et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998, 8:549-556.
57. Ye X., Yang Q., Wang Y., et al. Electrochemical behaviour of gold, silver, platinum and palladium on the glassy carbon electrode modified by chitosan and its application. Talanta 1998, 47:1099-1106.
58. Yancovitz M., Finelt N., Warycha M.A., et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007, 110:1107-1114.
59. Handley W. The bunterian lectures on the pathology of melanocytic growths in relation to their operative treatment. Lancet 1907, 169:927-933.
60. Pemberton O. Observations on the history, pathology, and treatment of cancerous diseases. Part I: melanosis 1858, Churchill, London.
61. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351:793-796.
62. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long-term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89:1495-1501.
63. Khayat D., Rixe O., Martin G., et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97:1941-1946.
64. Karakousis C.P., Balch C.M., Urist M.M., et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996, 3:446-452.
65. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350:757-766.
66. Breslow A., Macht S.D. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1977, 145:691-692.
67. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438-441.
68. Harris M.N., Shapiro R.L., Roses D.F. Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer 1995, 75:715-725.
69. Balch C.M., Urist M.M., Karakousis C.P., et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993, 218:262-267. [discussion: 267-9].
70. Lang P.G. Current concepts in the management of patients with melanoma. Am J Clin Dermatol 2002, 3:401-426.
71. Roses D.F., Harris M.N., Rigel D., et al. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983, 198:65-69.
72. Veronesi U., Cascinelli N., Adamus J., et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988, 318:1159-1162.
73. Sladden M.J., Balch C., Barzilai D.A., et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009, 4. CD004835.
74. Heaton K.M., Sussman J.J., Gershenwald J.E., et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998, 5:322-328.
75. Jaques D.P., Coit D.G., Brennan M.F. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989, 169:1-6.
76. Balch C.M., Soong S.J., Bartolucci A.A., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996, 224:255-263.
77. McCarthy W.H., Shaw H.M., Milton G.W. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985, 161:575-580.
78. Milton G.W., Shaw H.M., McCarthy W.H., et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982, 69:108-111.
79. Sim F.H., Taylor W.F., Ivins J.C., et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978, 41:948-956.
80. Murali R., Haydu L.E., Quinn M.J., et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 2012, 255(1):128-133.
81. Lourari S., Paul C., Gouraud P.A., et al. Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. J Eur Acad Dermatol Venereol 2011, [Epub ahead of print].
82. Bichakjian C.K., Halpern A.C., Johnson T.M., et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011, 65:1032-1047.
83. Wen D.R., Cochran A.J., Huang R.R., et al. Clinically relevant information from sentinel lymph node biopsies of melanoma patients. J Surg Oncol 2011, 104:369-378.
84. Callender G.G., McMasters K.M. Early versus delayed complete lymphadenectomy in melanoma: insight from MSLT I. Ann Surg Oncol 2011, 18:306-308.
85. Twomey P. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg 2007, 245:156-157.
86. Wong S.L., Brady M.S., Busam K.J., et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006, 13:302-309.
87. Schmidt C.R., Panageas K.S., Coit D.G., et al. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma. Ann Surg Oncol 2009, 16:948-952.
88. Wang X., Heller R., VanVoorhis N., et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994, 220:768-774.
89. Blaheta H.J., Schittek B., Breuninger H., et al. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998, 79:318-323.
90. Li W., Stall A., Shivers S.C., et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000, 231:795-803.
91. Bezu C., Coutant C., Salengro A., et al. Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol 2011, 20:e55-e59.
92. Cascinelli N., Bombardieri E., Bufalino R., et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006, 24:4464-4471.
93. Satzger I., Meier A., Hoy L., et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol 2011, 18:514-520.
94. McMasters K.M., Wong S.L., Edwards M.J., et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 2002, 9:137-141.
95. Basler G.C., Fader D.J., Yahanda A., et al. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol 1997, 36:403-408.
96. Doubrovsky A., Scolyer R.A., Murali R., et al. Diagnostic accuracy of fine needle biopsy for metastatic melanoma and its implications for patient management. Ann Surg Oncol 2008, 15:323-332.
97. Callery C., Cochran A.J., Roe D.J., et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982, 196:69-75.
98. Hafstrom L., Rudenstam C.M., Blomquist E., et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991, 9:2091-2094.
99. Wong J.H., Cagle L.A., Kopald K.H., et al. Natural history and selective management of in transit melanoma. J Surg Oncol 1990, 44:146-150.
100. Briggs J.C. Subungual malignant melanoma: a review article. Br J Plast Surg 1985, 38:174-176.
101. Glat P.M., Spector J.A., Roses D.F., et al. The management of pigmented lesions of the nail bed. Ann Plast Surg 1996, 37:125-134.
102. Ebskov L.B. Major amputation for malignant melanoma: an epidemiological study. J Surg Oncol 1993, 52:89-91.
103. Reintgen D.S., McCarty K.M., Cox E., et al. Malignant melanoma in black American and white American populations. A comparative review. JAMA 1982, 248:1856-1859.
104. Krementz E.T., Feed R.J., Coleman W.P., et al. Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg 1982, 195:632-645.
105. Clark W.H., Mihm M.C. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969, 55:39-67.
106. Zitelli J.A., Brown C., Hanusa B.H. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997, 37:236-245.
107. Jangjoo A., Forghani M.N., Mehrabibahar M., et al. Anaphylaxis reaction of a breast cancer patient to methylene blue during breast surgery with sentinel node mapping. Acta Oncol 2010, 49:877-878.
108. Kaufman G., Guth A.A., Pachter H.L., et al. A cautionary tale: anaphylaxis to isosulfan blue dye after 12 years and 3339 cases of lymphatic mapping. Am Surg 2008, 74:152-155.
109. Neves R.I., Reynolds B.Q., Hazard S.W., et al. Increased post-operative complications with methylene blue versus lymphazurin in sentinel lymph node biopsies for skin cancers. J Surg Oncol 2011, 103:421-425.
110. Kjems E., Krag C. Melanoma and pregnancy. A review. Acta Oncol 1993, 32:371-378.
111. Wong D.J., Strassner H.T. Melanoma in pregnancy. Clin Obstet Gynecol 1990, 33:782-791.
112. Baergen R.N., Johnson D., Moore T., et al. Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 1997, 121:508-511.
113. Dildy G.A., Moise K.J., Carpenter R.J., et al. Maternal malignancy metastatic to the products of conception: a review. Obstet Gynecol Surv 1989, 44:535-540.
114. Ances I.G., Pomerantz S.H. Serum concentrations of beta-melanocyte-stimulating hormone in human pregnancy. Am J Obstet Gynecol 1974, 119:1062-1068.
115. Sanchez J.L., Figueroa L.D., Rodriguez E. Behavior of melanocytic nevi during pregnancy. Am J Dermatopathol 1984, 6(Suppl):89-91.
116. Wong J.H., Sterns E.E., Kopald K.H., et al. Prognostic significance of pregnancy in stage I melanoma. Arch Surg 1989, 124:1227-1230. [discussion: 1230-1].
117. Houghton A.N., Flannery J., Viola M.V. Malignant melanoma of the skin occurring during pregnancy. Cancer 1981, 48:407-410.
118. Reintgen D.S., McCarty K.S., Vollmer R., et al. Malignant melanoma and pregnancy. Cancer 1985, 55:1340-1344.
119. Lederman J.S., Sober A.J. Effect of prior pregnancy on melanoma survival. Arch Dermatol 1985, 121:716.
120. Krag D.N., Weaver D.L., Alex J.C., et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993, 2:335-339. [discussion: 340].
121. Arcan P., Ibis E., Aras G., et al. Identification of sentinel lymph node in stage I-II breast cancer with lymphoscintigraphy and surgical gamma probe: comparison of Tc-99m MIBI and Tc-99m sulfur colloid. Clin Nucl Med 2005, 30:317-321.
122. Lin K.M., Patel T.H., Ray A., et al. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg 2004, 199:561-566.